BrightPath Biotherapeutics Co., Ltd. (4594.T)
JPY 46.0
(-2.17%)
JPY 46.0
(-2.17%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 72 Thousand JPY | -98.64% |
| 2022 | 5.28 Million JPY | -65.73% |
| 2021 | 15.4 Million JPY | 515.34% |
| 2020 | 2.5 Million JPY | -77.84% |
| 2019 | 11.3 Million JPY | -92.75% |
| 2018 | 155.8 Million JPY | -56.04% |
| 2017 | 354.41 Million JPY | -33.08% |
| 2016 | 529.61 Million JPY | -35.61% |
| 2015 | 822.55 Million JPY | 0.11% |
| 2014 | 821.62 Million JPY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 28 Thousand JPY | 460.0% |
| 2023 Q2 | 28 Thousand JPY | 75.0% |
| 2023 Q1 | 16 Thousand JPY | -68.63% |
| 2023 Q3 | 23 Thousand JPY | -17.86% |
| 2023 FY | 72 Thousand JPY | -98.64% |
| 2023 Q4 | 5000.00 JPY | -78.26% |
| 2022 Q4 | 51 Thousand JPY | -98.99% |
| 2022 Q3 | 5.05 Million JPY | 6817.81% |
| 2022 FY | 5.28 Million JPY | -65.73% |
| 2022 Q2 | 73 Thousand JPY | -31.13% |
| 2022 Q1 | 106 Thousand JPY | -99.3% |
| 2021 Q3 | 67 Thousand JPY | 31.37% |
| 2021 Q1 | 212 Thousand JPY | -67.83% |
| 2021 Q4 | 15.07 Million JPY | 22404.48% |
| 2021 Q2 | 51 Thousand JPY | -75.94% |
| 2021 FY | 15.4 Million JPY | 515.34% |
| 2020 Q4 | 659 Thousand JPY | 55.06% |
| 2020 FY | 2.5 Million JPY | -77.84% |
| 2020 Q1 | 319 Thousand JPY | -96.25% |
| 2020 Q2 | 1.1 Million JPY | 245.14% |
| 2020 Q3 | 425 Thousand JPY | -61.4% |
| 2019 Q2 | 1.13 Million JPY | 38.03% |
| 2019 Q4 | 8.5 Million JPY | 912.02% |
| 2019 Q1 | 823 Thousand JPY | -30.67% |
| 2019 Q3 | 840 Thousand JPY | -26.06% |
| 2019 FY | 11.3 Million JPY | -92.75% |
| 2018 FY | 155.8 Million JPY | -56.04% |
| 2018 Q4 | 1.18 Million JPY | -90.26% |
| 2018 Q3 | 12.18 Million JPY | -39.99% |
| 2018 Q2 | 20.3 Million JPY | -83.37% |
| 2018 Q1 | 122.12 Million JPY | 13.32% |
| 2017 Q1 | 90.63 Million JPY | -7.68% |
| 2017 Q2 | 92.04 Million JPY | 1.55% |
| 2017 Q3 | 63.95 Million JPY | -30.52% |
| 2017 Q4 | 107.77 Million JPY | 68.53% |
| 2017 FY | 354.41 Million JPY | -33.08% |
| 2016 FY | 529.61 Million JPY | -35.61% |
| 2016 Q3 | 114.4 Million JPY | -7.66% |
| 2016 Q2 | 123.88 Million JPY | -35.86% |
| 2016 Q1 | 193.14 Million JPY | -7.78% |
| 2016 Q4 | 98.18 Million JPY | -14.18% |
| 2015 FY | 822.55 Million JPY | 0.11% |
| 2015 Q4 | 209.44 Million JPY | 6.2% |
| 2015 Q3 | 197.2 Million JPY | -5.91% |
| 2015 Q1 | 206.31 Million JPY | 0.0% |
| 2015 Q2 | 209.59 Million JPY | 1.59% |
| 2014 FY | 821.62 Million JPY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 4.77 Billion JPY | 99.998% |
| PRISM BioLab Co.,LTD | 112.92 Million JPY | 99.936% |
| GNI Group Ltd. | 26.01 Billion JPY | 100.0% |
| Linical Co., Ltd. | 12.3 Billion JPY | 99.999% |
| Trans Genic Inc. | 13.08 Billion JPY | 99.999% |
| MEDINET Co., Ltd. | 661.54 Million JPY | 99.989% |
| Soiken Holdings Inc. | 5.15 Billion JPY | 99.999% |
| Cytori Cell Research Institute, Inc. | 1.56 Billion JPY | 99.995% |
| AnGes, Inc. | 152.98 Million JPY | 99.953% |
| OncoTherapy Science, Inc. | 610.11 Million JPY | 99.988% |
| Nxera Pharma Co., Ltd. | 12.76 Billion JPY | 99.999% |
| Immuno-Biological Laboratories Co., Ltd. | 816.7 Million JPY | 99.991% |
| NanoCarrier Co., Ltd. | 135.5 Million JPY | 99.947% |
| Carna Biosciences, Inc. | 1.62 Billion JPY | 99.996% |
| CanBas Co., Ltd. | - JPY | -Infinity% |
| D. Western Therapeutics Institute, Inc. | 428.36 Million JPY | 99.983% |
| RaQualia Pharma Inc. | 1.9 Billion JPY | 99.996% |
| Chiome Bioscience Inc. | 682.46 Million JPY | 99.989% |
| Kidswell Bio Corporation | 2.43 Billion JPY | 99.997% |
| PeptiDream Inc. | 28.71 Billion JPY | 100.0% |
| Oncolys BioPharma Inc. | 63.03 Million JPY | 99.886% |
| Ribomic Inc. | - JPY | -Infinity% |
| SanBio Company Limited | - JPY | -Infinity% |
| Healios K.K. | 121 Million JPY | 99.94% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 39.88 Million JPY | 99.819% |
| Delta-Fly Pharma, Inc. | - JPY | -Infinity% |
| StemRIM | - JPY | -Infinity% |
| CellSource Co., Ltd. | 4.51 Billion JPY | 99.998% |
| FunPep Company Limited | 530 Thousand JPY | 86.415% |
| Kringle Pharma, Inc. | 69.25 Million JPY | 99.896% |
| Stella Pharma Corporation | 269.49 Million JPY | 99.973% |
| TMS Co., Ltd. | - JPY | -Infinity% |
| Noile-Immune Biotech Inc. | 316.81 Million JPY | 99.977% |
| Cuorips Inc. | 23.1 Million JPY | 99.688% |
| K Pharma,Inc. | 1 Billion JPY | 99.993% |
| Takara Bio Inc. | 43.5 Billion JPY | 100.0% |
| ReproCELL Incorporated | 2.42 Billion JPY | 99.997% |
| PhoenixBio Co., Ltd. | 1.71 Billion JPY | 99.996% |
| StemCell Institute Inc. | 2.48 Billion JPY | 99.997% |
| Japan Tissue Engineering Co., Ltd. | 2.51 Billion JPY | 99.997% |
| CellSeed Inc. | 190.13 Million JPY | 99.962% |